author-photo

Phuong Tran

Bristol-Myers Squibb

5

Papers

7

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

2021
Show All
- Source
- Cite
- Save
Citations (0)